Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 7, 2014; 20(29): 9862-9871
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9862
Table 2 RAF, MEK and PI3K/mTOR inhibitors presently in the status of clinical trial in colorectal cancer
DrugTargetManufacturerPhaseIndication
SorafenibBRAFBayerIIColon cancer (combination with cetuximab)
PLX4032BRAFV600EPlexxikonIMelanoma, colon cancer
XL281BRAFExelixisISolid tumors
GSK1120212MEKGlaxoSmithKlineISolid tumors, Lymphoma
AZD6244MEKAstraZenecaIIColon cancer (combination with capecitabine)
AS703026MEKEMD SeronoISolid tumors
GDC-0973MEKGenentechISolid tumors
RO5126766MEKHoffman-La RocheISolid tumors
TAK-733MEKMilleniumISolid tumors
RDEA119MEKArdea BiosciencesISolid tumors
BGT226PI3KNovartisI/IISolid tumors, Her2 positive Breast Cancer
XL147PI3KExelixisISolid tumors, Lymphoma
XL765PI3KExelixisISolid tumors
BEZ235PI3KNovartisISolid tumors
GDC-0941PI3KGenentechISolid tumors
PX-866PI3KProIXISolid tumors
SF1126PI3KSemaforeISolid tumors
EverolimusmTORNovartisIIColon cancer (combination with cetuximab)